全文获取类型
收费全文 | 6174篇 |
免费 | 391篇 |
国内免费 | 266篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 96篇 |
妇产科学 | 185篇 |
基础医学 | 577篇 |
口腔科学 | 228篇 |
临床医学 | 679篇 |
内科学 | 1528篇 |
皮肤病学 | 82篇 |
神经病学 | 503篇 |
特种医学 | 76篇 |
外国民族医学 | 11篇 |
外科学 | 690篇 |
综合类 | 611篇 |
现状与发展 | 5篇 |
预防医学 | 497篇 |
眼科学 | 78篇 |
药学 | 428篇 |
3篇 | |
中国医学 | 141篇 |
肿瘤学 | 390篇 |
出版年
2024年 | 15篇 |
2023年 | 420篇 |
2022年 | 274篇 |
2021年 | 1061篇 |
2020年 | 716篇 |
2019年 | 431篇 |
2018年 | 311篇 |
2017年 | 300篇 |
2016年 | 265篇 |
2015年 | 287篇 |
2014年 | 492篇 |
2013年 | 525篇 |
2012年 | 206篇 |
2011年 | 246篇 |
2010年 | 164篇 |
2009年 | 163篇 |
2008年 | 160篇 |
2007年 | 129篇 |
2006年 | 104篇 |
2005年 | 91篇 |
2004年 | 85篇 |
2003年 | 63篇 |
2002年 | 63篇 |
2001年 | 59篇 |
2000年 | 32篇 |
1999年 | 28篇 |
1998年 | 28篇 |
1997年 | 29篇 |
1996年 | 13篇 |
1995年 | 18篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 3篇 |
排序方式: 共有6831条查询结果,搜索用时 281 毫秒
91.
92.
Ping-Tao Tseng Chun-Pai Yang Kuan-Pin Su Tien-Yu Chen Yi-Cheng Wu Yu-Kang Tu Pao-Yen Lin Brendon Stubbs Andre F. Carvalho Yutaka J. Matsuoka Dian-Jeng Li Chih-Sung Liang Chih-Wei Hsu Yen-Wen Chen Yow-Ling Shiue 《Journal of pineal research》2020,69(2):e12663
Although exogenous melatonin supplementation has been suggested to be effective for episodic migraine prophylaxis, there is no conclusive evidence comparing the efficacy of exogenous melatonin supplementation to the other FDA-approved pharmacotherapy for episodic migraine prophylaxis. The aim of the current network meta-analysis (NMA) was to compare the efficacy of exogenous melatonin supplementation in patients with episodic migraine. The randomized placebo-controlled trials or randomized controlled trials (RCTs) incorporating a placebo in the study designs were included in our analyses. All of the NMA procedures were conducted under the frequentist model. The primary outcome was changes in frequency of migraine days and response rate after migraine prophylaxis with melatonin supplementation or pharmacological interventions. We included 25 RCTs in total with 4499 patients (mean age = 36.0 years, mean female proportion = 78.9%). The NMA demonstrated that migraine prophylaxis with oral melatonin 3 mg/d (immediate-release) at bedtime was associated with the greatest improvement in migraine frequency [mean difference = −1.71 days, 95% confidence interval (CI): −3.27 to −0.14 days compared to placebo] and the second highest response rate (odds ratio = 4.19, 95% CI = 1.46 to 12.00 compared to placebo). Furthermore, oral melatonin 3 mg (immediate-release) at bedtime was the most preferred pharmacological intervention among all of the investigated interventions when improvements in migraine frequency, response rate, dropout rate, and rates of any adverse events were taken into account. This pilot NMA suggests the potential prophylactic role of exogenous melatonin supplementation in patients with episodic migraine. 相似文献
93.
94.
95.
96.
97.
98.
Background:Ulcerative colitis (UC) is a chronic non-specific intestinal inflammatory disease with unknown etiology. In recent years, the global incidence has been increasing. Sijunzi decoction (SJZD) is a traditional Chinese medicine that has been used for treatment of other diseases in previous studies as it has no side effects and it has a pharmacological effect in gastrointestinal function, immune system, ulcers, and tissue repair.Methods:PubMed, Embase, Cochrane Library, GeenMedical, China National Knowledge Infrastructure, Chinese Sci-tech Journals full-text Database, Chinese Biomedical Database, and Chinese Science Citation Database were searched to screen the related literatures of “ulcerative colitis” and “Jiawei Sijunzi decoction”. The research data extracted from above studies was analyzed by Review Manager 5.3 and Stata14.2 software.Results:This systematic review and meta-analysis will evaluate the efficacy and safety of Jiawei SJZD in the treatment of UC and provide effective evidence for clinical use.Conclusion:In this study, the published evidence of modified SJZD in the treatment of UC was systematically summarized and evaluated, so that it can be better applied in clinic.INPLASY registration number:INPLASY2020100102 相似文献
99.
《The British journal of oral & maxillofacial surgery》2021,59(7):742-751
A systematic review and network meta-analysis was conducted to compare different commercially available xenograft materials used in maxillary sinus floor elevation surgery (MSFES). Embase, PubMed, the Cochrane Library, Web of Science, Scopus, LILACS, and grey literature were searched up to 13 July 2020. Only randomised controlled trials (RCTs) were included. A frequentist network meta-analysis using a random effects model compared different commercially available xenograft materials. The primary outcomes were the percentage of newly-formed bone and residual bone-substitute rate. Both were measured by histomorphometric analysis from bone biopsies obtained during preparation of the implant site. Of the 659 studies initially identified, 11 involving 242 MSFES were included in the quantitative analyses. A total of six bone-substitute materials were analysed (Bio-Oss® (Geistlich Pharma), InduCera® Dual Coat, Lumina-Bone Porous® (Critéria), Osseous® (SIN - Sistema de Implantes Nacional), THE Graft® (Purgo Biologics), and Osteoplant Osteoxenon® (Bioteck)). The P-score estimation showed that Osteoplant Osteoxenon® produced the most newly-formed bone and reabsorbed faster than other xenograft materials after six months. The combination of Bio-Oss® plus bone marrow aspirate concentrate (BMAC) significantly increased the percentage of newly-formed bone compared with Bio-Oss® alone. In contrast, the addition of Emdogain® (Straumann) and leucocyte and platelet-rich fibrin (L-PRF) to Bio-Oss® did not significantly improve the amount of regenerated bone. Study-level data indicated that the percentage of newly-formed bone differs among commercially available xenograft materials. Osteoplant Osteoxenon® seems to result in the highest amount of new bone in MSFES. 相似文献
100.